

Certificate of Analysis

BDG Synthesis certifies that this reference material meets or exceeds the specifications stated herein.

leil Beare

Neil Beare, PhD, Director 24 June 2015

Name: Saxagliptin TFA Salt

CAS Number: 361442-04-8 (free base)

Structure:

Molecular Weight: $C_{18}H_{25}N_3O_2 \cdot C_2HF_3O_2 = 429.43$

Lot Number: BDG 14015.3

Appearance: White, crystalline solid

Corrected Purity: 99.2 % (HPLC) - 1.8 % (water) = 97.4 %

Re-test Date: 24 June 2020

Storage and Handling: Temperature: refrigerate for prolonged storage; may be handled and shipped at

ambient temperature.

Humidity: not believed to be hygroscopic; may be handled in normal laboratory

atmosphere.

Light: protect from strong sunlight.

Caution: only experienced laboratory personnel should handle the material.

Identity and Purity

Proton NMR Spectrum

Identity: the signals are consistent with the proposed structure and in accord with literature where available.

Residual Solvents: no residual solvents are observed.

Impurities: traces of unidentified impurities are seen in the baseline.

Carbon-13 NMR Spectrum

Identity: the signals are consistent with the proposed structure and in accord with literature where available.

High-resolution Mass Spectrum (TOF MS ES+)

Found m/z 316.2023. $C_{18}H_{26}N_3O_2$ [M+H]⁺ requires m/z 316.2025. The deviation of 0.6 ppm is within normally accepted limits for the establishment of identity by HRMS.

HPLC

A broad, slightly tailing peak is observed (99.2 %). Note: in the absence of reference materials for preparing calibration curves, it is assumed that all peaks have the same detector response. Where possible, the conditions of analysis follow a pharmacopeial or literature method, or have been adapted from same.

Elemental Analysis

C 55.34, H 6.18, F 13.00, N 9.41 % Found: Requires: C 55.01, H 6.19, F 13.05, N 9.62 %

C₁₈H₂₅N₃O₂·C₂HF₃O₂·0.4H₂O $C_{18}H_{25}N_3O_2{\cdot}C_2HF_3O_2$ Requires: C 55.94, H 6.10, F 13.27, N 9.79 %

The elemental analyses fall slightly outside those expected for anhydrous material; the presence of water is reasonably expected from the method of purification and/or the type of material, and the "best-fit" hydrated molecular formula is given.

Karl-Fischer Analysis

Found: H₂O 1.8 %


H₂O 1.7 % $C_{18}H_{25}N_3O_2 \cdot C_2HF_3O_2 \cdot 0.4H_2O$ Requires:

Of necessity, only a small sample could be used and only a single or duplicate analysis performed. We are unable to state what the errors in the reported water content are, but recommend that the result be used, as the best available, when determining corrected purity.


The available quantity of custom-synthesised material is always small, and this limits the extent and type of analytical data which can be obtained. This Certificate is presented in descriptive format for use by analytical chemists who are trained in the use of custom-synthesised materials. Custom materials often contain higher levels of residual solvents and/or water, and we urge you to use the corrected purity where needed rather than the raw HPLC purity. This compound is intended for use as an analytical reference material and it is not for human administration. Structures are shown with relative stereochemistry unless otherwise specified.


The re-test date is assigned from experience gained with the material in the laboratory and/or on storage. It is not possible to perform formal storage studies because of the small amount of material available.

BDG SYNTHESIS




Lot Number: BDG 14015.3





Lot Number: BDG 14015.3



BDG - Analysis of Saxagliptin TFA Salt

Column : Phenomenex Luna C18(2) 5um 250 x 4.6 mm Guard : Phenomenex Security Guard C18 RP 4 x 3 mm


Mobile Phase: 84:16:0.04 Water: Acetonitrile: Trifluoroacetic Acid

Flow Rate: 1.0 mL/min

Sample Solvent: Initial Mobile Phase

Column Temperature : 30C Injection Volume : 10 uL Detection : UV at 212 nm

| Sample Name | BDG 14015.3 | Instrument | AnalyticalLC01 |
|-------------|------------------------------|---------------|----------------|
| Acquisition | 24/06/2015, 14:42:07 | Method (rev.) | LC10431m (4) |
| Sequence | BDG_24Jun2015b - Reprocessed | Vial Position | 24 |
| Operator | solvation010\cerityadmin | Injection | 1 of 1 |



Area Percent Report

| Peak# | RT | Peak Height | Peak Area | Width | Area % |
|-------|-----------|-------------|------------|------------|----------|
| 1 | 3.58 min | 3.0424 | 31.7321 | 0.1457 min | 0.098 % |
| 2 | 3.93 min | 3.6212 | 26.3432 | 0.1129 min | 0.081 % |
| 3 | 5.16 min | 3.1576 | 34.4061 | 0.1591 min | 0.106 % |
| 4 | 6.22 min | 3.4237 | 37.6483 | 0.1603 min | 0.116 % |
| 5 | 9.44 min | 8.2467 | 115.9986 | 0.2041 min | 0.356 % |
| 6 | 13.25 min | 830.6453 | 32295.6230 | 0.5376 min | 99.244 % |